Anti-angiogenic treatments, which often target the VEGF pathway, have been shown to ‘normalise’ tumour vasculature by increasing vessel maturity, leading to re-oxygenation of the tumour and decreased hypoxia in mouse models (Dickson et al., 2007; Winkler et al., 2004). Here, VEGFA is linked to neoplasm.